Fig. 2

Uptake of [¹⁷⁷Lu]Lu-DOTA-Miltuximab® in tumour-bearing BALB/c/nude mice. a Imaging of Cerenkov radiation from representative mice bearing DU-145-RFP-Luc xenografts on days 3 and 5 post intravenous injection of 6 MBq [¹⁷⁷Lu]Lu-DOTA-Miltuximab®. b, c Biodistribution in %injected activity (IA)/gram and %IA/organ, respectively, of [¹⁷⁷Lu]Lu-DOTA-Miltuximab® in tumour-bearing BALB/c/nude mice on day 3 (n = 3), day 5 (n = 2), day 7 (n = 2) and day 27 endpoint (n = 6) post injection of a 6 MBq dose, assessed by gamma counting of organs ex vivo. Shown are mean with SEM